Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Crohn's Disease
Crohn's Disease
Boehringer Ingelheim adds second AI partner in a month
Endpoints
Wed, 05/6/20 - 12:14 pm
Boehringer Ingelheim
artificial intelligence
BERG
Bayesian AI
biomarkers
Crohn's Disease
inflammatory bowel disease
Celltrion showcases positive one-year results for subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis
Pharmaceutical Business Review
Mon, 02/17/20 - 10:20 am
Celltrion
clinical trials
CT-P13
Crohn's Disease
ulcerative colitis
Janssen trials ultrasound-guided approach to treating Crohn’s
Pharmaforum
Fri, 02/14/20 - 10:41 am
JNJ
Janssen
guided ultrasound
Stelara
Crohn's Disease
Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease
Endpoints
Wed, 11/13/19 - 11:22 pm
Takeda
Finch Therapeutics
microbiome
Crohn's Disease
Provention Bio's J&J-licensed Crohn's drug stumbles in mid-stage study
Endpoints
Wed, 10/23/19 - 10:12 am
Provention Bio
JNJ
Crohn's Disease
clinical trials
PRV-6527
$60M B round to propel Landos through Phase II IBD trials
BioCentury
Wed, 08/14/19 - 11:07 am
Landos Biopharma
clinical trials
ulcerative colitis
Crohn's Disease
BT-11
Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease
Pharmaceutical Business Review
Wed, 05/22/19 - 09:55 am
Eli Lilly
Crohn's Disease
mirikizumab
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Enpoints
Sun, 10/28/18 - 07:47 pm
Takeda
Shire
inflammatory bowel disease
IBD
ulcerative colitis
Crohn's Disease
M&A
SHP647
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
CP Wire
Thu, 10/25/18 - 11:27 pm
Enterome
Takeda
Crohn's Disease
EB8018
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
Thu, 10/25/18 - 12:41 pm
Enterome
Takeda
Crohn's Disease
EB8018
Stelara Shines in Three Year Crohn's Disease Study
CP Wire
Wed, 10/24/18 - 02:43 pm
Janssen
JNJ
Stelara
Crohn's Disease
clinical trials
Stelara Shines in Three Year Crohn's Disease Study
Wed, 10/24/18 - 10:05 am
Jannsen
JNJ
Stelara
Crohn's Disease
Arena 3 for 3 as Crohn’s drug meets proof-of-concept test
Fierce Biotech
Tue, 09/25/18 - 10:01 am
Arena Pharmaceuticals
olorinab
Crohn's Disease
RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3
Fierce Biotech
Mon, 07/30/18 - 11:23 am
Redhill Biopharma
clinical trials
Crohn's Disease
RHB-104
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Fierce Pharma
Wed, 07/11/18 - 11:35 am
JNJ
Tremfya
MorphoSys
Janssen
Crohn's Disease
clinical trials
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
Yahoo/Zacks.com
Mon, 02/19/18 - 04:18 pm
AbbVie
Upadacitinib
Crohn's Disease
J&J strikes potential $1B JAK inhibitor deal with Theravance
Biopharma Dive
Wed, 02/7/18 - 10:06 am
JNJ
JAK inhibitors
Theravance
TD-1473
drug development
Crohn's Disease
ulcerative colitis
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Yahoo/Reuters
Thu, 12/14/17 - 09:18 am
Pfizer
biosimilars
JNJ
Remicade
Ifixi
rheumatoid arthritis
Crohn's Disease
Price Hikes Insulate Celgene From a Failure
Motley Fool
Wed, 10/25/17 - 10:41 pm
Celgene
drug pricing
GED-301
Crohn's Disease
With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII
Endpoints
Thu, 09/21/17 - 08:49 am
JNJ
Provention Bio
IBD
inflammatory bowel disease
PRV-6527
Crohn's Disease
PRV-300
ulcerative colitis
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »